AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

另一项进展是，JMP Securities在强劲的第四季度业绩超出预期后，维持Halozyme的"市场表现优于大盘"评级，将股票目标价提高至78美元。H.C. Wainwright在公司报告收入略高于一致预期后，也将Halozyme的目标价提高至72美元，维持买入评级。Halozyme与默沙东就其皮下注射Keytruda候选产品的专利纠纷仍是焦点，JMP ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

周四，JMP Securities维持对Halozyme Therapeutics（NASDAQ:HALO）的"市场优于大盘"评级和78.00美元的目标价。此次重申评级是在制药巨头默沙东集团对Halozyme的皮下注射Keytruda候选药物相关专利提出质疑之后。默沙东向专利审判和上诉委员会（PTAB）提交了授权后复审请求，涉及Halozyme改良型透明质酸酶专利，这些专利是该公司专有药物输送技术 ...

AbbVie has expanded the availability of SKYRIZI in Canada for ulcerative colitis, strengthening its presence in the ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.